Boston Scientific Corporation BSX

BSX stock has fallen 55.5% over the past year and trades around $43.72, near its 52-week low. The options market prices a one-year range of roughly $28.46 to $67.16, implying about two-thirds odds of finishing within that band. A $28 floor would cut about $15.26 from the current price (roughly 35%), while a $67 ceiling offers about $23.44 (roughly 54% gain). The market also assigns roughly 16% chance of ending below $28.46. Implied volatility at 43.1% slightly exceeds the stock’s 38.4% trailing realization. Management has cut 2026 guidance again, citing WATCHMAN headwinds and competitive erosion in electrophysiology. A cyberattack in August disrupted manufacturing and orders, potentially affecting 2026 results. Outside WATCHMAN, growth is expected to pick up in H2 2026 and accelerate in 2028 with ICE imaging and the Penumbra deal; a 2027 WATCHMAN label update could unlock upside. Position size is the key decision. Cyberattack disruption and WATCHMAN headwinds could meaningfully alter BSX's trajectory, amplified by potential upside from ICE and Penumbra catalysts.

Cordis won FDA clearance for Selution SLR, a sirolimus-eluting balloon for coronary in-stent restenosis (ISR). It’s the first US-approved sirolimus balloon; Cordis argues it’s noninferior to usual care, with 15.2% target lesion failure (TLF) vs 13.5% for standard care across patients, but in single-layer ISR the rates were 14.2% vs 6.5%. U.S. physicians now have immediate access to Selution SLR, offering an alternative to uncoated balloons and to Boston Scientific’s paclitaxel-coated Agent, cleared in 2024. BSX has cited Agent as a growth driver in its cardiovascular business. Cordis, once part of J&J and later sold to Cardinal Health and Hellman & Friedman, led efforts in sirolimus balloons with MedAlliance (CE mark). In Europe, sirolimus devices compete with Concept Medical’s Magic Touch and B. Braun’s SeQuent SCB. Adds direct US competition to BSX's balloon portfolio and may erode share growth in ISR treatment.

Boston Scientific (BSX) rose 2.74% to $44.92 in the latest session as the Dow fell 0.36% and the Nasdaq gained 0.45%. Shares have fallen 10.79% over the past month, lagging the Medical sector (-3.65%) and the S&P 500 (+1.27%). Investors will watch the upcoming earnings release; the consensus calls for $0.77 per share for the quarter, up 2.67% year over year, and $5.28 billion in revenue, up 4.22%. For the full year, estimates stand at $3.27 per share on $21.29 billion in revenue, about 6.86% and 6.08% growth, respectively. Analysts have been tweaking estimates recently, with Zacks Rank at #4 Sell. Valuation shows a forward P/E of 13.35 vs. the Medical-Products industry's 20.16 and a PEG of 1.02 (industry 1.76). The Medical-Products industry ranks 98th of 250 in Zacks' Industry Rank. Earnings expectations and mixed analyst revisions could moderately influence BSX's near-term sentiment and valuation.

Boston Scientific outlines a two-year pipeline of launches designed to drive incremental growth. In Interventional Cardiology, the SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter is slated for the first half of 2027, backed by FRACTURE trial data showing 30-day freedom from major adverse cardiac events and high procedural success in severely calcified CAD. In Endoscopy, FDA clearance for RIVOS aims to consolidate exchanges and streamline biliary drainage procedures, with positive early case feedback. Enrollment continues in THRIVE, evaluating the TIVUS Ultrasound System for renal denervation; the company expects the SoniVie acquisition to bring this technology to market in 2028. In Cardiac Rhythm Management, PRECEDENT defibrillation platform is targeted for the second half of 2027. In Electrophysiology, FARAPULSE has accelerated pulsed-field ablation, with U.S. PFA revenues now about 80% of AFib market; long-term growth hinges on FARAWAVE Ultra (2027) and FARAFLEX (2028). Several high-potential launches and regulatory milestones across multiple segments through 2027–28 could materially alter BSX's growth trajectory despite current competitive and earnings headwinds.

Boston Scientific (BSX) stock slumped 55% and now trades at a discount. 55% slump signals major negative effects on valuation and future trajectory.

Boston Scientific Corporation stock lost over half its value despite rising sales, reflecting deep investor concerns over factors such as debt levels or competitive pressures that outweighed revenue gains and pressured market valuation. Sustained stock halving despite sales growth signals major ongoing concerns likely to constrain financing options and depress valuation multiples for years.

Boston Scientific recalls LUX Dx Cardiac Monitor due to delayed atrial fibrillation alerts. Product recall risks regulatory scrutiny and temporary disruption to cardiac monitoring sales.

Boston Scientific Corporation is relying on acquisitions to fuel long-term growth. Acquisitions represent major strategic moves that can significantly alter the company's trajectory and investor sentiment.

Boston Scientific reported Q2 earnings, evaluated against peers in the medical devices and supplies diversified sector. Q2 earnings analysis offers moderate insight into financial results and peer positioning without indicating major strategic shifts.

Medtronic raised its 2027 outlook citing broad-based growth momentum. Stronger outlook at competitor Medtronic signals potential competitive pressure on Boston Scientific market share and investor sentiment.

Boston Scientific warned of missing its guidance due to material impact from a cybersecurity incident, triggering a decline in shares. Cybersecurity incident triggers guidance miss and share drop, pointing to significant operational disruption and investor reaction.

Boston Scientific missed 2026 guidance after suffering a cyberattack. Cyberattack leading to missed 2026 guidance signals major operational disruption and negative effects on financial trajectory.

Boston Scientific Corporation reported that a cyberattack will hurt its 2026 results and make it unlikely to meet net sales growth and EPS guidance ranges. Cyberattack forces Boston Scientific to miss 2026 sales and EPS targets.

Cybersecurity incident disrupts Boston Scientific operations, making it unlikely to meet net sales guidance. Cybersecurity incident disrupts operations and blocks net sales guidance, pressuring near-term performance and sentiment.

Cyberattack on Boston Scientific disrupts sales and reduces profits, triggering sharp stock decline. Cyberattack directly impairs sales and profits at Boston Scientific impacting short-term performance.

Boston Scientific's 2026 growth outlook has weakened, prompting questions over potential recovery ahead for the company. Weakened 2026 growth outlook signals moderate pressure on Boston Scientific financial trajectory and investor sentiment.

Cyberattack disrupts Boston Scientific operations, making the company unlikely to meet its financial guidance. Cyberattack causes missed guidance with moderate effects on near-term financials and sentiment.

Boston Scientific unlikely to meet earnings guidance after cyberattack, triggering stock decline. Cyberattack triggers earnings guidance miss and stock drop but leaves long-term trajectory intact.

Boston Scientific will not meet guidance due to cyberattack. Cyberattack forces missed guidance with short-term effects on operations and investor views.

Boston Scientific Corporation progresses toward recovery after a cyberattack. Cyberattack recovery may temporarily disrupt operations and affect market sentiment without fundamentally altering long-term trajectory.

Boston Scientific (BSX) has dealt with product recalls and cyberattack disruptions that may alter its investment narrative and future outlook. Recalls and cyberattacks threaten Boston Scientific's product reliability, regulatory standing, and operational continuity.

Boston Scientific Corporation stock growth potential faces assessment for upside delivery to investors. Stock upside analysis may shift near-term investor views without changing core operations.

Boston Scientific's ICVT business gains momentum, prompting questions on sustainability of growth. ICVT momentum indicates moderate effects on future performance without altering core trajectory.

Boston Scientific suffers cyberattack damage alongside weak 2026 guidance, pressuring operations and prompting investor questions on whether BSX stock merits a sell. Cyberattack plus weak 2026 outlook directly threatens Boston Scientific operations and growth trajectory.

Boston Scientific (BSX) may be 23% undervalued after product recalls and a cyber incident. Recalls and cyber incident create operational risks and temporary market pressure for Boston Scientific.

Boston Scientific Corporation issues multiple worldwide product recalls. Multiple worldwide product recalls can reduce sales, invite regulatory scrutiny and weigh on stock performance.

Boston Scientific stock slumped 55% and now appears undervalued to investors. A 55% stock drop reflects material operational or market setbacks with moderate ongoing effects on performance.

BSX presents two factors supporting continued attention alongside one cautionary element for investors evaluating the stock. Balanced view identifies moderate influences on operations and sentiment without major trajectory changes.

Boston Scientific Corporation (BSX) states a cyberattack has disrupted its product manufacturing operations. Manufacturing disruption from cyberattack may cause temporary production delays and impact near-term financial results.

Abbott received CE mark approval for its new left atrial appendage closure device. Abbott's CE mark win adds direct competition to Boston Scientific in the European LAA closure market.